Table 1.

The characteristics of children with systemic juvenile idiopathic arthritis treated with anakinra (n = 45).

Characteristics	Complete Responders, n = 28	Nonresponders, n = 17	p
Female	16 (57.1)	9 (52.9)	0.78
Age at symptom onset, yrs	4 (0.75–15.7)	5 (1–4.6)	0.46
Age at diagnosis, yrs	4.3 (0.9–15.9)	5.3 (2–13)	0.46
Age at initiation of anakinra, yrs	6.5 (1.6–16.1)	8 (2.8–13.2)	0.49
Disease duration at initiation of anakinra, mos	6 (1–142)	24 (2–84)	0.17
Dose of anakinra, mg/kg daily	2 (2–4)	2 (2–5)	0.46
PGA, 0–10 scale, 10 worst	5 (2–7)	5 (4–8)	0.84
Fever	28 (100)	17 (100)	—
Rash	22 (78.6)	11 (64.7)	0.32
Hepatomegaly	9 (32.1)	6 (35.3)	0.82
Splenomegaly	11 (39.3)	5 (29.4)	0.54
Generalized lymphadenopathy	11 (39.3)	4 (23.5)	0.27
Serositis	7 (25)	4 (23.5)	1
Hemoglobin, g/dl	10 (7.6–15.1)	10.3 (6.5–12.6)	0.72
WBC count, × 10³/mm³	12.75 (2.4–52.9)	11.3 (4–21)	0.26
Neutrophil count, × 10³/mm³	8.45 (0.6–43.6)	8.5 (1.9–18.6)	0.78
Platelet count, × 10³/mm³	480 (219–883)	504 (202–820)	0.59
ESR, mm/h, normal range 0–20	46 (10–120)	49 (28–120)	0.81
CRP, mg/dl, normal range 0–0.8	9.41 (1–34)	7.18 (1.6–26)	0.26
Fibrinogen, mg/dl, normal range 144–430	409.5 (206–983)	406.5 (238–1200)	0.74
Ferritin, ng/ml, normal range 11–307	620.5 (312–8849)	162 (50–692)	0.056
Systemic manifestation score	5 (2–8)	3 (2–8)	0.13
Duration of anakinra treatment, mos	17 (3–60)	10 (2–50)	0.26
Still using anakinra at 1 yr	24 (85.7)	7 (41.2)	0.002
Still using corticosteroids at 1 yr	1 (3.6)	14 (82.4)	< 0.001
Presence of flare under anakinra treatment	4 (14.3)	15 (88.2)	< 0.001

Numeric variables are presented as median (min–max) values. Nominal variables are presented as n (%). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PGA: physician’s global assessment; WBC: white blood cell.